Menu Search
Equities

Sinopharm Group Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1099:HKG

Sinopharm Group Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (HKD)20.98
  • Today's Change-0.14 / -0.66%
  • Shares traded4.18m
  • 1 Year change+7.15%
  • Beta0.5141
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 26-Feb-26
Select bar for recommendation details.
Recommendations26-Feb-26
Buy4
Outperform7
Hold6
Sell0
Strong Sell0

Share price forecast in CNY

The 14 analysts offering 12 month price targets for Sinopharm Group Co Ltd have a median target of 22.96, with a high estimate of 24.66 and a low estimate of 19.47. The median estimate represents a 9.42% increase from the last price of 20.98.
High17.5%24.66
Med9.4%22.96
Low-7.2%19.47

Dividends

In 2024, Sinopharm Group Co Ltd reported a dividend of 0.69 CNY, which represents a 20.09% decrease from last year. The 9 analysts covering the company expect dividends of 0.72 CNY for the upcoming fiscal year, an increase of 2.96%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)-20.09%
More ▼

Earnings history & estimates in CNY

Sinopharm Group Co Ltd reported annual 2024 earnings of 2.26 per share on Mar 23, 2025.
Average growth rate+0.40%
More ▼

Revenue history & estimates in CNY

Sinopharm Group Co., Ltd. had revenues for the full year 2024 of 584.51bn. This was 2.02% below the prior year's results.
Average growth rate+6.54%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.